Table 1.

Respondent characteristics.

Characteristic	Statistic N = 210
Country; n (%)
France	29 (14)
Germany	26 (12)
Italy	30 (14)
United Kingdom	20 (10)
United States of America	105 (50)
Sex; n (%)
Female	99 (47)
Male	111 (53)
Employment status; n (%)	N = 207*
Full time	76 (38)
Part time due to spasticity	72 (35)
Part time (not due to spasticity)	10 (5)
Do not work due to spasticity	32 (16)
Do not work (not due to spasticity)	15 (8)
Student	2 (1)
Age (years); mean [95% CI]	47.2 [45.9, 48.5]
Age category; n (%)
<40 years old	39 (19)
41–50 years old	110 (52)
51–60 years old	48 (23)
>60 years old	13 (6)
Age at time of event (years); mean [95% CI]	42.7 [41.3, 44.2]
Etiology; mean [95% CI]
Stroke	45.3 [43.3, 47.4]
TBI	40.6 [37.5, 43.7]
SCI	40.8 [38.6, 43.0]
Time since event (years); mean [95% CI]	4.6 [3.8, 5.4]
Time category; n (%)
<2 years	44 (21)
2–5 years	118 (57)
6–10 years	26 (12)
>10 years	19 (9)
Do not remember	3 (1)
Symptoms experienced in past year; n (%)
Muscle stiffness/rigidity	148 (70)
Muscle spasms	132 (63)
Muscle pain	108 (51)
Unwanted movements of the affected limb	86 (41)
Difficulties moving my leg, falling, tripping, loss of balance	104 (50)
Difficulties moving my arm/hand, extending my arm, opening my hand	82 (39)
Currently receiving BoNT-A; n (%)	203 (97)
AbobotulinumtoxinA (Dysport)	41 (20)
IncobotulinumtoxinA (Xeomin)	44 (21)
OnabotulinumtoxinA (Botox)	112 (53)
BoNT-A product unknown	N = 6 (3)
No (stopped in past 12 months)	7 (3)
Time since first BoNT-A injection
<2 years	102 (48)
2–5 years	88 (42)
>5 years	12 (6)
Do not remember	8 (4)
Injected limbs; n (%)
1 Upper limb only	53 (25)
Both upper limbs	37 (18)
1 Lower limb only	42 (20)
Both lower limbs	42 (20)
One side (upper and lower limbs)	31 (15)
Diagonal (upper and lower limbs)	4 (2)
≥2 Limbs	1 (0)

^*Employment status for respondents > 65 years old was not analyzed.